Lotus Eye Hospital And Institute Ltd (LOTUSEYE) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Lotus Eye Hospital And Institute Ltd on NSE and BSE, with an AI summary of each filing.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 11 Nov 2026, 5:30 am
LOTUS EYE HOSPITAL AND INSTITUTE LIMITED has informed the Exchange about Board Meeting to be held on 11-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 11 Nov 2026, 5:30 am
Lotus Eye Hospital And Institute Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2026 ,inter alia, to consider and approve the Unaudited ....
Intimation · 11 Nov 2026, 5:30 am
Lotus Eye Hospital Schedules Board Meeting for Q2 FY27 Results Lotus Eye Hospital and Institute Limited has scheduled a meeting of its Board of Directors on 11th Nov'26 to consider and approve the standalone unaudited financial results for the quarter and half-year ended 30th Sep'26. In accordance with SEBI Insider Trading Regulations, the company's trading window will reopen 48 hours after the declaration of the financial results.
The Company has opened its 11th branch at Erode.
Others (Uncategorized) · 31 Oct 2026, 1:21 am
Lotus Eye Hospital Expands Footprint With 11th Branch in Erode Lotus Eye Hospital and Institute Limited announced the operational launch of its 11th branch in Erode, Tamil Nadu, effective 30th Oct'26. The launch marks the continuation of the company's regional footprint expansion in South India, supporting its long-term network growth strategy.
Voting results and Scrutinizer Report for the 29th Annual General Meeting
Annual General Meeting · 25 Sept 2026, 12:26 am
Summary of proceedings of the 29th Annual General Meeting
Annual General Meeting · 24 Sept 2026, 1:19 am
Annual Report for the financial year 2025-26
Others (Uncategorized) · 01 Sept 2026, 6:32 pm
AGM Notice
Annual General Meeting · 01 Sept 2026, 6:20 pm
Launches "Lotus Optique", a new optical store.
Press Release · 27 Aug 2026, 8:54 pm
Lotus Eye Hospital Launches New Optical Retail Initiative Lotus Eye Hospital and Institute announced on Aug 27, '26, the launch of 'Lotus Optique,' a new optical retail store at its SITRA campus in Coimbatore. This initiative integrates the company's clinical eye care services with eyewear retail, offering branded frames and lenses. The new store aims to leverage the trusted 'Lotus' brand to capture the eyewear market. It features ZEISS VISUFIT 1000 3D scanning technology for frame fitting, marking a strategic expansion into a complementary vertical to enhance customer experience and company growth.
Standalone Unaudited Financial Results for the quarter ended June 30, 2026.
Financial Result · 11 Aug 2026, 1:11 am
Lotus Eye Hospital Q1 FY27 Net Profit Rises 12.7% YoY Lotus Eye Hospital reported a 12.7% YoY increase in net profit to ₹61.37 lakhs for Q1 FY27, up from ₹54.48 lakhs. Revenue from operations grew 26.2% YoY to ₹1,705.71 lakhs. Sequentially, the company swung to a profit from a loss of ₹31.95 lakhs in Q4 FY26, with revenue climbing 25.3% QoQ. Total expenses rose 25.2% YoY to ₹1,625.44 lakhs. The company reported a basic EPS of ₹0.30 for the quarter, compared to ₹0.26 in the previous year's quarter.
Approved Standalone Unaudited Financial Results for the quarter ended June 30, 2026.
Outcome · 11 Aug 2026, 12:08 am
Lotus Eye Hospital And Institute Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakhs) ■ Revenue: 1,706 (+26.2% YoY | +25.3% QoQ) ■ EBITDA: 294 (+99.5% YoY | +515.5% QoQ) ■ EBITDA Margin (%): 17.3 (+634 bps YoY | +1375 bps QoQ) ■ PAT: 61.4 (+12.6% YoY | Loss to Profit QoQ) ■ EPS (INR): 0.30 (+15.4% YoY | Loss to Profit QoQ)
Lotus Eye Hospital And Institute Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve Unaudited ....
Intimation · 10 Aug 2026, 5:30 am
Lotus Eye Hospital Board to Review Q1FY27 Results on 10th Aug'26 Lotus Eye Hospital and Institute Limited (NSE: LOTUSEYE) has scheduled a Board of Directors meeting on 10th Aug'26. The primary agenda is to consider and approve the standalone unaudited financial results for the first quarter ended 30th Jun'26. In compliance with SEBI insider trading regulations, the trading window for designated persons will reopen 48 hours after the financial results are declared to the stock exchanges. This meeting is a key event for tracking the company's Q1 performance.
Reappointment of Internal Auditor of the Company
Change in Management · 27 May 2026, 2:20 am
Lotus Eye Hospital Q4FY26 Results: Revenue Up, Reports Net Loss Lotus Eye Hospital reported Q4FY26 standalone results, posting a net loss of Rs. 31.95 lakhs versus a Rs. 25.23 lakh profit YoY. Revenue from operations for the quarter grew 18.2% YoY to Rs. 1,360.92 lakhs. For the full year FY26, net profit declined significantly to Rs. 8.04 lakhs from Rs. 73.93 lakhs in FY25, while annual revenue rose 8.4% YoY to Rs. 5,371.41 lakhs. Basic EPS for Q4FY26 was negative at Rs. (0.15) compared to Rs. 0.12 YoY.
Standalone Audited Financial Results For Quarter And Year Ended March 31, 2026 and reappointment of P Vishnu Adithan as Internal Auditor of the Company
Outcome · 27 May 2026, 2:13 am
Lotus Eye Hospital Q4FY26 Results Show Net Loss Amidst Higher Expenses Lotus Eye Hospital reported a Q4FY26 net loss of Rs. 31.95 lakhs versus a Rs. 25.23 lakhs profit YoY. Revenue from operations increased 18.2% YoY to Rs. 1,360.92 lakhs, while total expenses grew 30.1% YoY to Rs. 1,456.48 lakhs, driven by higher service and employee costs. For the full year FY26, net profit declined 89.1% to Rs. 8.04 lakhs from Rs. 73.93 lakhs in FY25, despite an 8.4% rise in revenue. The Board also approved the reappointment of its internal auditor for FY27.
Standalone Audited Financial Results for the quarter and year ended March 31, 2026.
Financial Result · 27 May 2026, 2:03 am
Lotus Eye Hospital And Institute Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakhs) ■ Revenue: 1,361 (+18.2% YoY | +0.4% QoQ) ■ EBITDA: 47.8 (-62.5% YoY | -27.2% QoQ) ■ EBITDA Margin (%): 3.5 (-757 bps YoY | -133 bps QoQ) ■ PAT: -32.0 (Profit to Loss YoY | -22.6% QoQ) ■ EPS (INR): -0.15 (Profit to Loss YoY | -15.4% QoQ)
Lotus Eye Hospital And Institute Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2026 ,inter alia, to consider and approve Standalone ....
Intimation · 26 May 2026, 5:30 am
Lotus Eye Hospital Board Meeting for Q4 and FY26 Results Lotus Eye Hospital and Institute Ltd's Board of Directors will meet on 26th May'26 to consider and approve the standalone audited financial results for the quarter and year ended 31st Mar'26. In accordance with SEBI regulations, the trading window for insiders will reopen 48 hours after the declaration of these financial results. This prior intimation was filed with the BSE (Scrip: 532998) and NSE (Scrip: LOTUSEYE) on 21st May'26.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sangeetha Sundaramoorthy
Acquisition/ Disposal of Shares · 08 May 2026, 8:25 pm
Promoter Group Member Increases Stake in Lotus Eye Hospital Sangeetha Sundaramoorthy, a member of the promoter group of Lotus Eye Hospital, acquired 14,28,571 shares through an inter-se transfer on 27 Feb'26. This transaction represents 6.8693% of the company's total share capital. Following the acquisition, her shareholding increased from 28.1391% (58,51,901 shares) to 35.0084% (72,80,472 shares). The total equity share capital of the company remains unchanged at Rs. 20,79,63,300. This move consolidates the promoter group's holding in the company.
Please refer the attachment
Others (Uncategorized) · 18 Apr 2026, 6:42 pm
Lotus Eye Hospital Confirms Non-Large Corporate Status Lotus Eye Hospital and Institute Limited (NSE: LOTUSEYE, BSE: 532998) informed exchanges on 18 Apr'26 that it does not qualify as a "Large Corporate" as of 31 Mar'26. This confirmation is pursuant to SEBI's circular from 19 Oct'23 regarding fund raising via debt securities. The company stated it does not fulfill the applicability criteria for this classification, exempting it from the related disclosure and fundraising requirements. This status provides flexibility and avoids the mandatory debt issuance obligations placed on larger entities.
Please refer attachment
Outcome · 17 Mar 2026, 10:43 pm
Lotus Eye Hospital Scraps NSE Delisting Plan Lotus Eye Hospital and Institute Limited's Board of Directors has decided not to proceed with the proposed voluntary delisting of its equity shares from the National Stock Exchange (NSE). The decision, made on 17 Mar'26, cites current market conditions, liquidity factors, and the need for investor convenience. The company's shares will continue to be listed and traded on both the BSE Limited (Scrip Code: 532998) and the National Stock Exchange (Scrip Code: LOTUSEYE).
Lotus Eye Hospital And Institute Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/03/2026 ,inter alia, to consider and approve the proposal ....
Intimation · 12 Mar 2026, 11:54 pm
Lotus Eye Hospital Board to Consider Voluntary NSE Delisting Lotus Eye Hospital and Institute Ltd's Board of Directors will meet on 17 Mar'26 to consider a proposal for the voluntary delisting of its equity shares from the National Stock Exchange (NSE). The company intends to maintain its listing on the BSE Limited, which provides a nationwide trading terminal. This action is being considered under the SEBI (Delisting of Equity Shares) Regulations, 2021. The proposal, if approved, will result in the company's shares ceasing to trade on the NSE platform.
Imposition of Fine
Others (Uncategorized) · 05 Mar 2026, 3:20 am
Lotus Eye Hospital Fined by Exchanges for SEBI LODR Non-Compliance Lotus Eye Hospital disclosed that BSE and NSE each imposed a fine of ₹2,17,120 for non-compliance with SEBI LODR Regulation 17(1A). The penalty pertains to the quarter ended Dec 31, '25. The company received the directive on Feb 27, '26, and stated the non-compliance was rectified on Jan 17, '26, via a postal ballot. Lotus Eye Hospital confirmed there is no material financial impact from this fine and has paid all previous fines levied up to the quarter ended Sep 30, '25.
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sangeetha Sundaramoorthy
Others (Uncategorized) · 02 Mar 2026, 9:59 pm
Promoter Group Share Transfer at Lotus Eye Hospital Sangeetha Sundaramoorthy, a promoter of Lotus Eye Hospital, will acquire 14,28,571 shares (a 6.87% stake) from fellow promoter Kavetha Sundaramoorthy. The transaction, valued at ₹70 per share, is scheduled for 27 Feb '26, per an agreement dated 02 Jun '25. Post-acquisition, Sangeetha Sundaramoorthy's holding will increase from 28.14% to 35.01%. This inter-se promoter transfer is exempt from an open offer under SEBI regulations. Kavetha Sundaramoorthy's stake will decrease from 9.61% to 2.75%.
Board comments on imposition of fine under Regulation 17(1A) of SEBI (LODR), 2015
Others (Uncategorized) · 12 Feb 2026, 7:05 pm
Lotus Eye Hospital Fined for SEBI LODR Non-Compliance Lotus Eye Hospital's board acknowledged a fine from BSE and NSE on 11 Feb '26 for non-compliance with SEBI LODR Regulation 17(1A). The penalty stems from a disagreement over whether a change in a director's designation constitutes a reappointment, a view held by the exchanges but not the company. Despite disagreeing, Lotus Eye Hospital paid the fine to ensure compliance and has committed to preventing future occurrences. The company has assured stakeholders of its steadfast commitment to corporate governance.
Appointment of Company Secretary & Compliance Officer
Change in Management · 12 Feb 2026, 5:09 pm
Lotus Eye Hospital Appoints New Company Secretary and Compliance Officer Lotus Eye Hospital and Institute Limited (NSE: LOTUSEYE) has appointed Mr. Prathish S as Company Secretary and Compliance Officer, effective 13 Feb'26. The decision was made by the Board of Directors on 11 Feb'26, based on the Nomination and Remuneration Committee's recommendation. Mr. Prathish S is an Associate Member of the ICSI and holds a Bachelor's degree from Shri Ram College of Commerce. He is experienced in secretarial compliance, corporate governance, and regulatory reporting.
Approved Unaudited Standalone Financial Results for the quarter and year ended December 31, 2025 and appointment of Company Secretary & Compliance Officer
Financial Result · 12 Feb 2026, 12:07 am
Lotus Eye Hospital reports Q3FY26 loss, appoints new Company Secretary Lotus Eye Hospital announced a Q3FY26 net loss of ₹26.07 lakhs, a significant decline from a net profit of ₹11.58 lakhs QoQ and a loss of ₹23.91 lakhs YoY. Revenue from operations for the quarter ended Dec 31, '25, stood at ₹1,354.96 lakhs, up 10.6% YoY and 3.9% QoQ. Total expenses increased to ₹1,416.07 lakhs. The board also approved the appointment of Mr. Prathish S. as Company Secretary & Compliance Officer, effective Feb 13, '26.